The new diagnostic approach has the potential to enhance infectious diseases surveillance, and so is now being adapted to track immunity to COVID-19.
Unlike in the influenza pandemic in 1918, today we are better equipped to identify the elusive bug responsible for COVID-19.
Researchers have developed a new method to enable more timely diagnosis and treatment of urological cancers, ie, prostate, bladder and kidney cancers.
A new blood test can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any clinical signs or symptoms.
A new infection test, made up of sheets of paper patterned by lasers, will enable diagnosis at the point of care — helping doctors give patients the right treatment, and quickly.
The nanotechnology developed by University of Queensland scientists can detect and monitor extracellular vesicles (EVs) in the bloodstream.
Computed tomography (CT) of the chest demonstrates better sensitivity than reverse-transcription polymerase chain reaction (RT‑PCR) when it comes to diagnosing COVID‑19.
The test will detect the infection early in blood by embedding monoclonal antibodies against surface glycoproteins (GP) — one of the first detectable biomarkers of infection.
A novel non-invasive technique can successfully detect human papilloma virus-16 — the strain associated with oropharyngeal cancer — in saliva samples.
A new rapid test is expected to return a finding after just 60 to 90 min — and all it requires to diagnose asthma is a drop of blood and the immune cells it contains.
The urine test diagnoses aggressive prostate cancer and predicts whether patients will require treatment up to five years earlier than standard clinical methods.
Scientists have discovered markers in the blood that can differentiate between a benign mole and a melanoma in the eye, while also identifying if the cancer has spread.
The UK's National Cancer Research Institute has announced several promising new methods for detecting cancer early, as detailed at the 2019 NCRI Cancer Conference.
The test procedure is hoped to positively impact tuberculosis diagnosis in adults living in remote areas.
In contrast to liquid biopsies, which detect genetic mutations or other cancer-related alterations in DNA, the technology focuses on modifications to DNA known as methyl groups.